[NK activities in cancer patients--their modification by an immunopotentiator].
NK activity of patients with cancer against gastric carcinoma cell line KATO-III, lung carcinoma cell line A-549 as well as K-562 was significantly lower than that in the control group. We investigated in vitro effects of immunopotentiator, OK-432, on the effector cells of both healthy donors and cancer patients. NK activity of healthy donors was clearly augmented after treatment of effector cells with OK-432. NK activity of some patients with cancer, however, showed no augmentation after OK-432 treatment. These results might be helpful for monitoring cancer patients from immunological view point.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D001688:Biological Products / Q000494:pharmacology*; D002478:Cells, Cultured; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D010844:Picibanil / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D001688:Biological Products; D010844:Picibanil